大规模测序揭示乳腺癌和卵巢癌易感基因关联
IMPORTANCE: Since the discovery of BRCA1 and BRCA2, multiple high- and moderate-penetrance genes have been reported as risk factors for hereditary breast cancer, ovarian cancer, or both; however, it is unclear whether these findings represent the complete genetic landscape of the…
要点
- ATM、CHEK2、PALB2、MSH6与乳腺癌风险增加相关。
- MSH6、RAD51C、TP53、ATM与卵巢癌风险增加相关。
- 未支持BRIP1、RAD51C、RAD51D及MSH2、PMS2与乳腺癌关联。
核心结论
- 大规模外显子测序确认了ATM、CHEK2、PALB2、MSH6与乳腺癌风险的关联,以及MSH6、RAD51C、TP53、ATM与卵巢癌风险的关联。
- 研究未支持BRIP1、RAD51C、RAD51D或MSH2、PMS2与乳腺癌风险的关联。
研究设计与样本
- 同时以Genome Aggregation Database作为参考对照进行病例对照分析。
主要发现
- 在9,639例乳腺癌患者中,3,960例(41.1%)为早发性(诊断时≤45岁),123例(1.3%)为男性,男性诊断年龄大于女性(平均[SD]年龄,61.8[12.8] vs 48.6[11.4]岁)。
- 在2,051例卵巢癌女性中,445例(21.7%)在45岁或以下诊断。
- 与乳腺癌风险相关的4个非BRCA基因及比值比:ATM(OR 2.97;95%CI 1.67-5.68)、CHEK2(OR 2.19;95%CI 1.40-3.56)、PALB2(OR 5.53;95%CI 2.24-17.65)、MSH6(OR 2.59;95%CI 1.35-5.44)。
- MRN复合体基因和CDKN2A均与乳腺癌或卵巢癌风险增加无关。
临床怎么用
- 对于乳腺癌或卵巢癌患者,尤其是早发性或男性乳腺癌,基因检测应考虑包括ATM、CHEK2、PALB2、MSH6等非BRCA易感基因。
- 卵巢癌遗传风险评估中应关注MSH6、RAD51C、TP53和ATM。
- 对于BRIP1、RAD51C、RAD51D、MSH2、PMS2与乳腺癌的关联应谨慎解读,不推荐常规用于乳腺癌风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Since the discovery of BRCA1 and BRCA2, multiple high- and moderate-penetrance genes have been reported as risk factors for hereditary breast cancer, ovarian cancer, or both; however, it is unclear whether these findings represent the complete genetic landscape of these cancers. Systematic investigation of the genetic contributions to breast and ovarian cancers is needed to confirm these findings and explore potentially new associations. OBJECTIVE: To confirm reported and identify additional predisposition genes for breast or ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS: In this sample of 11 416 patients with clinical features of breast cancer, ovarian cancer, or both who were referred for genetic testing from 1200 hospitals and clinics across the United States and of 3988 controls who were referred for genetic testing for noncancer conditions between 2014 and 2015, whole-exome sequencing was conducted and gene-phenotype associations were examined. Case-control analyses using the Genome Aggregation Database as a set of reference controls were also conducted. MAIN OUTCOMES AND MEASURES: Breast cancer risk associated with pathogenic variants among 625 cancer predisposition genes; association of identified predisposition breast or ovarian cancer genes with the breast cancer subtypes invasive ductal, invasive lobular, hormone receptor-positive, hormone receptor-negative, and male, and with early-onset disease. RESULTS: Of 9639 patients with breast cancer, 3960 (41.1%) were early-onset cases (≤45 years at diagnosis) and 123 (1.3%) were male, with men having an older age at diagnosis than women (mean [SD] age, 61.8 [12.8] vs 48.6 [11.4] years). Of 2051 women with ovarian cancer, 445 (21.7%) received a diagnosis at 45 years or younger. Enrichment of pathogenic variants were identified in 4 non-BRCA genes associated with breast cancer risk: ATM (odds ratio [OR], 2.97; 95% CI, 1.67-5.68), CHEK2 (OR, 2.19; 95% CI, 1.40-3.56), PALB2 (OR, 5.53; 95% CI, 2.24-17.65), and MSH6 (OR, 2.59; 95% CI, 1.35-5.44). Increased risk for ovarian cancer was associated with 4 genes: MSH6 (OR, 4.16; 95% CI, 1.95-9.47), RAD51C (OR, not estimable; false-discovery rate-corrected P = .004), TP53 (OR, 18.50; 95% CI, 2.56-808.10), and ATM (OR, 2.85; 95% CI, 1.30-6.32). Neither the MRN complex genes nor CDKN2A was associated with increased breast or ovarian cancer risk. The findings also do not support previously reported breast cancer associations with the ovarian cancer susceptibility genes BRIP1, RAD51C, and RAD51D, or mismatch repair genes MSH2 and PMS2. CONCLUSIONS AND RELEVANCE: The results of this large-scale exome sequencing of patients and controls shed light on both well-established and controversial non-BRCA predisposition gene associations with breast or ovarian cancer reported to date and may implicate additional breast or ovarian cancer susceptibility gene candidates involved in DNA repair and genomic maintenance.
引用
- Lu HM, Li S, Black MH, et al. Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing. JAMA Oncol. 2019. PMID: 30128536. doi:10.1001/jamaoncol.2018.2956
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。